Leqvio FDA Approval
Large integrated program to establish Leqvio® as part of the
standard of care in ASCVD management
Lipid lowering
Registration trials
ORION-3 (Ph2 extension)
ORION-5 (Ph3 HoFH)
ORION-8 (Ph3 extension)
Geographic expansion
ORION-14 (China)
Outcomes
Secondary Prevention
ORION-4 (Oxford)
VICTORION-2-PREVENT
Primary Prevention
ORION-17 (Oxford)
Healthcare system
partnerships
NHS collaboration
VICTORION-SPIRIT (UK)
Implementation
science and RWE
Initiation of treatment
VICTORION-INITIATE (US)
Post-ACS
VICTORION-INCEPTION (US)
ORION-18 (China)
ORION-15 (Japan)
Diverse patient populations
ORION-13 (V-YOUTH)
ORION-16 (V-YOUTH)
>75,000 patients in >50 countries; Program expansion underway
ASCVD - Atherosclerotic Cardiovascular Disease.
RWE Real World Evidence
14 LeqvioⓇ FDA Approval | December 23, 2021 | Novartis Investor Presentation
U NOVARTIS | Reimagining MedicineView entire presentation